A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)

Inclusion Criteria:

Inclusion criteria include, but are not limited to:

All Participants

• Is a continuous non-smoker or moderate smoker (≤ 10 cigarettes per day orequivalent) for at least 3 months prior to the first dosing

• Has a body mass index (BMI) ≥ 18.0 and ≤ 42.0 kg/m^2 at the screening visit

Participants with severe renal impairment (RI) (Group 1):

• Has severely impaired renal function as determined by estimated glomerularfiltration rate (eGFR) using the 2021 Chronic Kidney Disease EpidemiologyCollaboration (CKD-EPI) creatinine equation

Participants with end-stage renal disease (ESRD) (Group 2):

• Has ESRD maintained on stable outpatient regimen of intermittent high-fluxhemodialysis (HD) (at least 3 times per week) for a minimum of 3 hours per dialysissession, using a complication free well-maintained arteriovenous fistula orarteriovenous graft, for at least 3 months prior to first dosing and is expected andplanning to continue HD during the study and at least up to the follow-up visit

Healthy Control Participants (Group 3):

• Has normal renal function

Exclusion Criteria:

Exclusion criteria include, but are not limited to:

All Participants:

• Has a history or presence of any of the following: Adrenal insufficiency; Hepaticimpairment; Clinically significant hypotension; cardiac arrhythmia; cardiacconduction abnormalities or recurrent unexplained syncopal events; Second- orthird-degree atrioventricular (AV) heart block (except in participants with afunctional artificial pacemaker); Clinically significant sick sinus syndrome; Anysystemic fungal infection; Hypothyroidism; Chronic infection

• Has a first-degree relative with multiple unexplained syncopal events, unexplainedcardiac arrest, or sudden cardiac death, or has a known family history of aninherited arrhythmia syndrome (including Brugada syndrome)

• Has a history of cancer (malignancy)

• Is positive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV)

Participants with Severe RI (Group 1):

• Has a history or presence of renal artery stenosis

• Has had a renal transplant

• Has ESRD requiring HD

Participants with ESRD (Group 2):

• Has required frequent emergent HD (≥ 3) within a year prior to the first dosing

• Has a history or presence of renal artery stenosis.

• Has had a functioning renal transplant within the past 2 years